cancer treatment
| 3 min read
The therapy exploits the properties of a neutrophil-derived enzyme to selectively kill tumor cells while preserving healthy immune cells.
| 1 min read
ProBioGen announced the commercial launch of Ziihera®, a bispecific antibody for HER2-positive biliary tract cancer developed with its GlymaxX® technology.
| 7 min read
Most cancer cells have the wrong number of chromosomes, known as aneuploidy. Scientists are finding ways to target this flaw with new treatments.
Page 1 of 1 - 3 Total Items
